open access

Vol 12, No 4 (2018)
Case report
Published online: 2019-01-21
Get Citation

Interdisciplinary approach in a patient diagnosed with prostate cancer and spine metastases

Marek Widenka, Wojciech Leppert
DOI: 10.5603/PMPI.2018.0013
·
Palliat Med Pract 2018;12(4):207-213.

open access

Vol 12, No 4 (2018)
Case report
Published online: 2019-01-21

Abstract

Prostate cancer is one of the malignant tumours in which treatment of bone metastases is a significant clinical problem. In this article 66-year-old patient diagnosed with prostate cancer and multiple metastases to all parts of the spine with accompanying neuropathic pain of severe intensity, which disabled self-moving of a patient is presented. The patient was not qualified for surgery during neurosurgeon consultation. During palliative care provision for the patient by an interdisciplinary team of Home Hospice composed pharmacology treatment of pain was introduced using oxycodone/naloxone, ketoprofen and adjuvant analgesics: zoledronate acid with calcium and vitamin D supplementation, pregabalin and dexamethasone. Stability of the spine was provided through high trunk orthosis in order to minimize the risk of spine damage associated with rehabilitation. A significant decrease in pain, constipation and anxiety intensity was achieved with an improvement of overall performance status and quality of life, which enabled a further anticancer treatment and palliative radiotherapy. The submitted case indicates on a necessity of palliative care provided by the interdisciplinary team for patients diagnosed with prostate cancer and dissemination to bones and severe pain intensity, which significantly increases a chance for obtaining satisfactory analgesia, improvement in the quality of life and a possibility of continuing anticancer and symptomatic treatment.
Palliat Med Pract 2018; 12, 4: 207–213

Abstract

Prostate cancer is one of the malignant tumours in which treatment of bone metastases is a significant clinical problem. In this article 66-year-old patient diagnosed with prostate cancer and multiple metastases to all parts of the spine with accompanying neuropathic pain of severe intensity, which disabled self-moving of a patient is presented. The patient was not qualified for surgery during neurosurgeon consultation. During palliative care provision for the patient by an interdisciplinary team of Home Hospice composed pharmacology treatment of pain was introduced using oxycodone/naloxone, ketoprofen and adjuvant analgesics: zoledronate acid with calcium and vitamin D supplementation, pregabalin and dexamethasone. Stability of the spine was provided through high trunk orthosis in order to minimize the risk of spine damage associated with rehabilitation. A significant decrease in pain, constipation and anxiety intensity was achieved with an improvement of overall performance status and quality of life, which enabled a further anticancer treatment and palliative radiotherapy. The submitted case indicates on a necessity of palliative care provided by the interdisciplinary team for patients diagnosed with prostate cancer and dissemination to bones and severe pain intensity, which significantly increases a chance for obtaining satisfactory analgesia, improvement in the quality of life and a possibility of continuing anticancer and symptomatic treatment.
Palliat Med Pract 2018; 12, 4: 207–213

Get Citation

Keywords

bone pain, treatment, opioids, pain, bone metastases, prostate cancer

About this article
Title

Interdisciplinary approach in a patient diagnosed with prostate cancer and spine metastases

Journal

Palliative Medicine in Practice

Issue

Vol 12, No 4 (2018)

Pages

207-213

Published online

2019-01-21

DOI

10.5603/PMPI.2018.0013

Bibliographic record

Palliat Med Pract 2018;12(4):207-213.

Keywords

bone pain
treatment
opioids
pain
bone metastases
prostate cancer

Authors

Marek Widenka
Wojciech Leppert

References (54)
  1. Hayat MJ, Howlader N, Reichman ME, et al. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007; 12(1): 20–37.
  2. Zdrojowy R. Kwas zoledronowy – znaczenie w zapobieganiu i leczeniu powikłań związanych z przerzutami do kości. Przegl Urol. 2004; 23: 16–20.
  3. Heidecke V, Rainov NG, Burkert W. Results and outcome of neurosurgical treatment for extradural metastases in the cervical spine. Acta Neurochir (Wien). 2003; 145(10): 873–80; discussion 880.
  4. Ortiz Gómez JA. The incidence of vertebral body metastases. Int Orthop. 1995; 19(5): 309–311.
  5. Camins MB, Jenkins AL, Singhal A, Perrin RG. Tumors of the vertebral axis: benign, primary malignant, and metastatic tumors. In: Winn RH, Youmans JR. ed. Youmans neurological surgery. 5th ed. Saunders Company, Philadelphia 2004: 4835–4868.
  6. Jacobs WB, Perrin RG. Evaluation and treatment of spinal metastases: an overview. Neurosurg Focus. 2001; 11(6): e10.
  7. Coleman R. Skeletal complications of malignancy. Cancer. 1997; 80(S8): 1588–1594, doi: 10.1002/(sici)1097-0142(19971015)80:8+<1588::aid-cncr9>3.0.co;2-g.
  8. Perrin RG, Laxton AW. Metastatic spine disease: epidemiology, pathophysiology, and evaluation of patients. Neurosurg Clin N Am. 2004; 15(4): 365–373.
  9. Steinmetz MP, Mekhail A, Benzel EC. Management of metastatic tumors of the spine: strategies and operative indications. Neurosurg Focus. 2001; 11(6): e2.
  10. Holman PJ, Suki D, McCutcheon I, et al. Surgical management of metastatic disease of the lumbar spine: experience with 139 patients. J Neurosurg Spine. 2005; 2(5): 550–563.
  11. Drosik K, Krzakowski M, Jarosz J, et al. Bisfosfoniany w zapobieganiu i kontroli zdarzeń kostnych u chorych z przerzutami nowotworów złośliwych do kości. Onkol Prakt Klin. 2006; 2: 152–164.
  12. Ibrahim A, Crockard A, Antonietti P, et al. Does spinal surgery improve the quality of life for those with extradural (spinal) osseous metastases? An international multicenter prospective observational study of 223 patients. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2007. J Neurosurg Spine. 2008; 8(3): 271–278.
  13. Patchell R, Tibbs P, Regine W, et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. The Lancet. 2005; 366(9486): 643–648.
  14. Harel R, Angelov L. Spine metastases: current treatments and future directions. Eur J Cancer. 2010; 46(15): 2696–2707.
  15. Jang RW, Caraiscos VB, Swami N, et al. Simple prognostic model for patients with advanced cancer based on performance status. J Oncol Pract. 2014; 10(5): e335–e341.
  16. Bisaga W, Dorazil M, Dobrogowski J, et al. Porównanie przydatności wybranych skal oceny bólu neuropatycznego u pacjentów z przewlekłymi zespołami bólowymi: krótkie doniesienie. Med Paliat Prakt. 2011; 5: 22–26.
  17. De Walden-Gałuszko K, Majkowicz M. Ocena jakości opieki paliatywnej w teorii i praktyce. Akademia Medyczna w Gdańsku, Gdańsk 2000: 34–36.
  18. van der Linden YM, Dijkstra SP, Vonk EJA, et al. Dutch Bone Metastasis Study Group. Prediction of survival in patients with metastases in the spinal column: results based on a randomized trial of radiotherapy. Cancer. 2005; 103(2): 320–328.
  19. Cole J, Patchell R. Metastatic epidural spinal cord compression. The Lancet Neurology. 2008; 7(5): 459–466.
  20. Helweg-Larsen S, Sørensen PS. Symptoms and signs in metastatic spinal cord compression: a study of progression from first symptom until diagnosis in 153 patients. Eur J Cancer. 1994; 30A(3): 396–398.
  21. Yang Z, Yang D, Xie L, et al. Treatment of metastatic spinal tumors by percutaneous vertebroplasty versus percutaneous vertebroplasty combined with interstitial implantation of 125I seeds. Acta Radiol. 2009; 50(10): 1142–1148.
  22. Witham TF, Khavkin YA, Gallia GL, et al. Surgery insight: current management of epidural spinal cord compression from metastatic spine disease. Nat Clin Pract Neurol. 2006; 2(2): 87–94; quiz 116.
  23. Costelloe CM, Rohren EM, Madewell JE, et al. Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol. 2009; 10(6): 606–614.
  24. Guillevin R, Vallee JN, Lafitte F, et al. Spine metastasis imaging: review of the literature. J Neuroradiol. 2007; 34(5): 311–321.
  25. Daldrup-Link HE, Franzius C, Link TM, et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol. 2001; 177(1): 229–236.
  26. Fehlings MG, David KS, Vialle L, et al. Decision making in the surgical treatment of cervical spine metastases. Spine (Phila Pa 1976). 2009; 34(22 Suppl): S108–S117.
  27. Kotlińska–Lemieszek A, Deskur-Śmielecka E, Kluziak M, et al. Leczenie bólów nowotworowych – w oparciu o aktualną wiedzę. Now Lek. 2011; 80: 22–31.
  28. Widenka M, Leppert W. The role of transdermal buprenorphine in the treatment ofchronic pain in elderly patients. Ból. 2016; 17(3): 53–63.
  29. King SJ, Reid C, Forbes K, et al. A systematic review of oxycodone in the management of cancer pain. Pain Pract. 2014; 14: 32–42.
  30. Morlion BJ, Mueller-Lissner SA, Vellucci R, et al. Oral Prolonged-Release Oxycodone/Naloxone for Managing Pain and Opioid-Induced Constipation: A Review of the Evidence. Pain Pract. 2018; 18(5): 647–665.
  31. Szczudlik A, Dobrogowski J, Wordliczek J, et al. Rozpoznanie i leczenie bólu neuropatycznego: przegląd piśmiennictwa i zalecenia Polskiego Towarzystwa Badania Bólu i Towarzystwa Neurologicznego – część pierwsza. Ból. 2014; 15: 8–18.
  32. Raptis E, Vadalouca A, Stavropoulou E, et al. Pregabalin vs. opioids for the treatment of neuropathic cancer pain: a prospective, head-to-head, randomized, open-label study. Int J Clin Pract. 2010; 64: 1301–1309.
  33. Bandelow B, Michaelis S, Wedekind D. Treatment of anxiety disorders. Ann Oncol. 2006; 17: 986–989.
  34. Nishihara M, Arai YCP, Yamamoto Y, et al. Combinations of low–dose antidepressants and low–dose pregabalin as useful adjuvants to opioids for intractable, painful bone metastases. Palliat Med. 2011; 25: 454–470.
  35. Tsuzuki S, Park SH, Eber MR, et al. Skeletal complications in cancer patients with bone metastases. Int J Urol. 2016; 23(10): 825–832.
  36. Masclee GMC, Valkhoff VE, Coloma PM, et al. Risk of upper gastrointestinal bleeding from different drug combinations. Gastroenterology. 2014; 147(4): 784–792.e9; quiz e13.
  37. So A, Chin J, Fleshner N, et al. Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice. Can Urol Assoc J. 2012; 6(6): 465–470.
  38. Coleman RE. Bisphosphonates: clinical experience. Oncologist. 2004; 9 Suppl 4: 14–27.
  39. Fleisch H. Bisphosphonates: Background to the pharmacological development. In: Fleisch H. ed. Bisphosphonates in bone disease: from the laboratory to the patient. Wyd. 4. Academic Press Inc., London, New York 2000.
  40. Saad F, Gleason DM, Murray R, et al. Zoledronic Acid Prostate Cancer Study Group. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002; 94(19): 1458–1468.
  41. Tupikowski K, Zdrojowy R. Zapobieganie uszkodzeniom tkanki kostnej oraz ich leczenie u chorych na raka gruczołu krokowego – zagadnienia wybrane. Przegląd Urologiczny. 2007; 43: 73–78.
  42. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008; 83(9): 1032–1045.
  43. Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N Engl J Med. 2003; 349(17): 1676–9; discussion 1676.
  44. Durie BGM, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005; 353(1): 99–102; discussion 99.
  45. Litwiniuk M, Staszkiewicz A. Martwica kości szczęk po długotrwałym stosowaniu bisfosfonianów. Onkol Prakt Klin. 2007; 3: 306–310.
  46. Lutz S. The role of radiation therapy in controlling painful bone metastases. Curr Pain Headache Rep. 2012; 16(4): 300–306.
  47. Cao XY, Liu YS, Lei MX, et al. [Comparison of curative effect and prognosis analysis of patients with spinal metastases treated by percutaneous vertebroplasty combined with postoperative radiotherapy and radiotherapy alone]. Zhonghua Yi Xue Za Zhi. 2016; 96(47): 3805–3810.
  48. Rolski W, Kiprian D, Kawecki A. Radioterapia paliatywna w leczeniu przerzutów do kości. Med Paliat. 2011; 2: 95–100.
  49. Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol. 2007; 25(11): 1423–1436.
  50. Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005; 97(11): 798–804.
  51. Lutz S, Berk L, Chang E, et al. American Society for Radiation Oncology (ASTRO). Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011; 79(4): 965–976.
  52. De Felice F, Piccioli A, Musio D, et al. The role of radiation therapy in bone metastases management. Oncotarget. 2017; 8(15): 25691–25699.
  53. van der Linden YM, Lok JJ, Steenland E, et al. Dutch Bone Metastasis Study Group. Single fraction radiotherapy is efficacious: a further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment. Int J Radiat Oncol Biol Phys. 2004; 59(2): 528–537.
  54. Ryan CJ, Saylor PJ, Everly JJ, et al. Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data. Oncologist. 2014; 19(10): 1012–1018.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Medycyna Paliatywna w Praktyce dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl